arXiv 2607.044462026-07-07physics.med-ph

粒子治疗合作组织治疗效率小组委员会关于患者特定质量保证的风险评估报告

PTCOG Treatment Efficiency Subcommittee Risk Assessment Report on Patient-Specific Quality Assurance

Paul Scherrer Institute（保罗谢勒研究所）；The Skandion Clinic（斯坎迪翁诊所）；St. Jude Children’s Research Hospital（圣裘德儿童研究医院）；Johns Hopkins Medicine（约翰霍普金斯医学）；Harvard Medical School（哈佛医学院）；Mayo Clinic（梅奥诊所）

Frank Emert, Christina Vallhagen Dahlgren, Chin-Cheng Chen, Heng Li, Jay Flanz, Daniel Robertson

备注：: PTCOG Treatment Efficiency Subcommittee White Paper; certified version accepted June 10, 2026; 135 pages, 28 figures; will be hosted on the official PTCOG website and assigned a DOI by Elsevier

阅读 PDF

arXiv 页面 ↗HTML 原文 ↗

AI总结：

该报告将质子治疗中患者特定质量保证视为工作流程中的风险控制策略，用过程驱动的失效模式与效应分析，对不同质量保证方法评分，给出风险控制优势，支持基于风险的混合质量保证架构。

摘要：

在笔形束扫描质子治疗（PBS-PT）中，特定患者质量保证（PSQA）常被视为纯粹的技术验证任务。本粒子治疗合作组织（PTCOG）治疗效率小组委员会白皮书将PSQA构建为工作流程嵌入的风险控制策略，并探讨不同PSQA方法如何重塑相同的临床风险格局。通过通用的PBS-PT过程驱动的失效模式和效应分析（pFMEA），在共同的无PSQA基线和三种PSQA途径下，对20个过程步骤中的44种经过验证的与PSQA相关的失效模式进行评分……

英文摘要：

Patient-specific quality assurance (PSQA) in pencil beam scanning proton therapy (PBS-PT) is often treated as a purely technical verification task. This PTCOG Treatment Efficiency Subcommittee White Paper instead frames PSQA as a workflow-embedded risk-control strategy and asks how different PSQA approaches reshape the same clinical risk landscape. Using a generic PBS-PT process-driven Failure Mode and Effects Analysis (pFMEA), 44 validated PSQA-relevant failure modes across 20 process steps were scored under a common no-PSQA baseline and three PSQA pathways: measurement-based PSQA, log file-based PSQA, and independent secondary dose calculation. A staged mathematical formalism separates preparatory data-stage effects, method-specific full-stage verification, cumulative endstate effects, and a Data-to-Cum bridge that quantifies additional verification benefit on the baseline scale. In this expert-scored, baseline-anchored model, log file-based PSQA produced the largest cumulative workflow-level risk-score reduction, followed by measurement-based PSQA and independent secondary dose calculation. The ranking is not a winner-takes-all rule or probability-calibrated risk estimate; instead, each method shows distinct risk-control strengths in different workflow regions. The White Paper therefore supports a risk-informed hybrid PSQA architecture, where log file-based PSQA, measurement-based PSQA, and independent secondary dose calculation are assigned to the workflow segments in which their signatures are strongest. It provides a transparent, semi-quantitative, stage-resolved framework for institutions seeking to evaluate, implement, or evolve PSQA in PBS-PT and emphasizes that log file-based PSQA must itself be supported by validated and governed log data and treatment records.

机构、总结、中文摘要均由AI分析而来，可能存在错误，请以论文正文为准。